Literature DB >> 22487283

Management of the nasolacrimal system during transnasal endoscopic medial maxillectomy.

Nader Sadeghi1, Arjun Joshi.   

Abstract

BACKGROUND: During transnasal endoscopic medial maxillectomy (TEMM) for sinonasal tumors, the nasolacrimal duct (NLD) is resected as it forms part of the medial wall of the maxillary sinus. This disrupts the nasolacrimal drainage system. To ensure that epiphora does not develop after such resection, an endoscopic dacryocystorhinostomy (DCR) is traditionally performed. This is based primarily on prior experience with open medial maxilloethmoidectomy. It is unclear whether a concurrent DCR during endoscopic medial maxillectomy is necessary, however. This study was designed to compare patients undergoing TEMM with or without concurrent DCR for postoperative patency of the NLD.
METHODS: This is a prospective cohort study comparing12 patients undergoing TEMM, 5 with concurrent DCR and 7 without, to assess for patency of the NLD system. In the group that underwent a concurrent DCR, a Jones silastic stent was inserted for 2-3 months. Patients were followed for a minimum of 1 year for assessment of epiphora. The patency of the NLD was judged by clinical and qualitative evidence for epiphora.
RESULTS: None of the patients in either group developed epiphora. All were completely symptom free for epiphora during the follow-up period.
CONCLUSION: It appears that after TEMM, patients do not develop epiphora, whether or not a concurrent DCR is performed. Hence, a concurrent DCR does not seem necessary during TEMM.

Entities:  

Mesh:

Year:  2012        PMID: 22487283     DOI: 10.2500/ajra.2012.26.3737

Source DB:  PubMed          Journal:  Am J Rhinol Allergy        ISSN: 1945-8932            Impact factor:   2.467


  1 in total

1.  Surgical relationship of the nasolacrimal system to the maxillary line: Performing safe mega antrostomy.

Authors:  Kathleen M Sarber; Peter D O'Connor; Mary S Doellman; Micaela J Dagucon; Philip G Chen; Kevin C McMains; Erik K Weitzel
Journal:  Allergy Rhinol (Providence)       Date:  2015-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.